Announced Tue, 29 Sept, 2026 · 10:52 IST
Symbiotec Pharmalab gets U.S. FDA EIR with VAI classification for Pithampur facility
SYMBIOTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+11.7%1-day move
₹1055.60
prior close
₹1116.85
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.8-0.4-0.2+11.7+13.4+10.5+9.2+6.9—————
Up moveDown movePending
AI summary
Symbiotec Pharmalab received an Establishment Inspection Report from the U.S. FDA for its Pithampur SEZ manufacturing facility in Madhya Pradesh. The inspection ran from August 10 to August 14, 2026, and ended with a Voluntary Action Indicated classification, meaning the facility requires no further regulatory action. VAI is a positive outcome that confirms compliance with U.S. FDA standards.
Likely market impact
Positive regulatory clearance for U.S. FDA inspected facility; supports continued exports to the U.S. and signals compliance with global quality standards.